Information Provided By: 
Fly News Breaks for January 18, 2017
IART, DSCI
Jan 18, 2017 | 09:35 EDT
Roth Capital analyst Scott Henry downgraded Derma Sciences (DSCI) to Neutral from Buy post the $7 per share cash acquisition offer from Integra LifeSciences (IART). The analyst does not expect another bidder to surface. He lowered his price target on Derma Sciences' shares to $7 from $8.50.
News For DSCI;IART From the Last 2 Days
There are no results for your query DSCI;IART
